Compile Data Set for Download or QSAR
maximum 50k data
Found 262 Enz. Inhib. hit(s) with all data for entry = 2934
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385676(4-{5- [(cyclopropylmethyl) amino]-[1,2,4] triazolo...)
Affinity DataIC50:  5nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385701(4-{7-[(oxetan-3- ylmethyl)amino]- [1,2,4]triazolo[...)
Affinity DataIC50:  5nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385711(4-(7-{[(4- fluorophenyl) methyl]amino}- [1,2,4]tri...)
Affinity DataIC50:  5nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM50239931(CHEMBL4067995 | US10287286, Example 142)
Affinity DataIC50:  8nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385707(4-(7-{[2- (dimethylamino) ethyl]amino}- [1,2,4]tri...)
Affinity DataIC50:  8nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385693(4-{7- [(cyclopropyl- methyl) amino]- [1,2,4]triazo...)
Affinity DataIC50:  9nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385702(4-{7-[(3,3,3- trifluoropropyl) amino]- [1,2,4]tria...)
Affinity DataIC50:  9nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM50239883(CHEMBL4090769 | US10287286, Example 5)
Affinity DataIC50:  10nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385700(4-{7-[(2,2- difluoroethyl) amino]- [1,2,4]triazolo...)
Affinity DataIC50:  10nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385674(4-[5- (dimethylamino)- [1,2,4]triazolo[1,5- a]pyri...)
Affinity DataIC50:  11nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385747(US10287286, Example 150)
Affinity DataIC50:  12nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385709(4-(7-{[(2- fluorophenyl) methyl]amino}- [1,2,4]tri...)
Affinity DataIC50:  13nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM50239889(CHEMBL4072842 | US10287286, Example 100)
Affinity DataIC50:  13nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385792(US10287286, Example 195 | cyclopropylmethyl N-[5-(...)
Affinity DataIC50:  14nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385853(US10287286, Example 251)
Affinity DataIC50:  17nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385706(4-{7-[(oxolan-2- ylmethyl)amino]- [1,2,4]triazolo[...)
Affinity DataIC50:  20nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385809(US10287286, Example 211)
Affinity DataIC50:  25nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385698(4-{7-[(oxolan-3- ylmethyl)amino]- [1,2,4]triazolo[...)
Affinity DataIC50:  25nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM50239888(CHEMBL4094292 | US10287286, Example 103)
Affinity DataIC50:  25nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385851(US10287286, Example 249)
Affinity DataIC50:  27nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385742(US10287286, Example 146)
Affinity DataIC50:  27nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385750(N-[5-(4-cyano-3- fluorophenyl)- [1,2,4]triazolo[1,...)
Affinity DataIC50:  28nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385710(4-(7-{[(3- fluorophenyl) methyl]amino}- [1,2,4]tri...)
Affinity DataIC50:  29nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM386909(US10287286, Example 260)
Affinity DataIC50:  29nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385680(4-(5-{[3- (dimethylamino) propyl]amino}- [1,2,4]tr...)
Affinity DataIC50:  29nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385820(US10287286, Example 219)
Affinity DataIC50:  30nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385688(4-[5- (cyclopropylamino)- [1,2,4]triazolo[1,5- a]p...)
Affinity DataIC50:  32nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385708(4-[7-(benzylamino)- [1,2,4]triazolo[1,5- a]pyridin...)
Affinity DataIC50:  33nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM50239937(CHEMBL4083851 | US10287286, Example 3)
Affinity DataIC50:  34nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM50239915(CHEMBL4067559 | US10287286, Example 6)
Affinity DataIC50:  34nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385694(4-{7-(2- methoxyethyl) amino}- [1,2,4]triazolo[1,5...)
Affinity DataIC50:  34nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385771(N-[5-(4-cyano-3- fluorophenyl)- [1,2,4]triazolo[1,...)
Affinity DataIC50:  34nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385850(US10287286, Example 248)
Affinity DataIC50:  35nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385808(US10287286, Example 210)
Affinity DataIC50:  36nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385697(4-{7-[(oxan-4- ylmethyl)amino]- [1,2,4]triazolo[1,...)
Affinity DataIC50:  37nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM50239890(CHEMBL4095005 | US10287286, Example 4)
Affinity DataIC50:  39nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385773(US10287286, Example 176)
Affinity DataIC50:  40nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385749(N-[5-(4- cyanophenyl)- [1,2,4]triazolo[1,5- a]pyri...)
Affinity DataIC50:  42nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385722(2-fluoro-4-(7-{[(3- methyloxetan-3- yl)methyl]amin...)
Affinity DataIC50:  47nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385748(N-[5-(4- cyanophenyl)- [1,2,4]triazolo[1,5- a]pyri...)
Affinity DataIC50:  47nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385719(US10287286, Example 124 | tert-butyl N-[5-(4- cyan...)
Affinity DataIC50:  49nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385766(N-[5-(4-cyano-3- fluorophenyl)- [1,2,4]triazolo[1,...)
Affinity DataIC50:  49nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385713(4-[7-(benzyloxy)- [1,2,4]triazolo[1,5- a]pyridin-5...)
Affinity DataIC50:  49nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM50239921(CHEMBL4075128 | US10287286, Example 7)
Affinity DataIC50:  50nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM50239913(CHEMBL4102714 | US10287286, Example 223)
Affinity DataIC50:  52nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385714(US10287286, Example 120 | tert-butyl N-[5-(4- cyan...)
Affinity DataIC50:  52nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385721(2-fluoro-4-{7- [(3,3,3- trifluoropropyl)- amino][1...)
Affinity DataIC50:  53nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385794(1-methylpiperidin-4-yl N-[5- (4-cyano-3 -fluorophe...)
Affinity DataIC50:  53nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM50239898(CHEMBL4070540 | US10287286, Example 2)
Affinity DataIC50:  54nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM385712(4-[7- (cyclopropyl- methoxy)- [1,2,4]triazolo[1,5-...)
Affinity DataIC50:  54nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 262 total ) | Next | Last >>
Jump to: